Pharmaceutical composition containing levosimendan or its pharmaceutically acceptable salt as active ingredient
An active ingredient and pharmaceutical technology, applied in the field of pharmaceutical preparations, can solve problems such as unreported, coagulation side effects, etc., and achieve the effect of low toxicity and safe medication for patients
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0047] Example 1 Levosimendan Injection
[0048] Component Amount (g)
[0049] Levosimendan 2.5g
[0050] Solutol® HS15 10g
[0051] Anhydrous citric acid 2g
[0052] Add absolute ethanol to 1000ml
[0053] A concentrated solution was prepared by dissolving citric acid, Solutol(R) HS15 and levosimendan in absolute ethanol in a sterile formulation container. The resulting bulk solution was filtered through a sterile filter (0.22 μm). The sterilization method of this product is sterile filtration, because ethanol solution has the risk of explosion and cannot be sterilized by autoclaving. The sterile-filtered bulk solution was aseptically filled into vials for injection and closed with Dacron membrane rubber stoppers for infusion.
Embodiment 2
[0054] Example 2 Levosimendan Oral Liquid
[0055] Component Dosage
[0056] Levosimendan 12.5mg
[0057] Solutol® HS15 30mg
[0058] Absolute ethanol 2.5ml
[0059] Corn oil" 10ml
[0060] Makes 12ml
[0061] The levosimendan composition is mixed with corn oil, and stirred evenly under stirring conditions to obtain a clear oily liquid, which can be used as an oral liquid or soft capsule as the content of the soft capsule.
Embodiment 3
[0063] Component Dosage
[0064] Levosimendan 12.5mg
[0065] Mannitol 280mg
[0066] Solutol® HS15 50mg
[0067] 0.2mol / L disodium hydrogen phosphate 1.46ml
[0068] 0.2mol / L sodium dihydrogen phosphate 0.14ml
[0069] Add water for injection to 3ml
[0070] Take levosimendan, Solutol(R) HS15, mannitol, add disodium hydrogen phosphate and sodium dihydrogen phosphate solution, stir to dissolve completely (PH is 7.8), add 3 mg of activated carbon, continue stirring for 30 min, decarbonize, add water for injection to set Make up to 3ml, 0.22um microporous membrane filter to sterilize. Under aseptic conditions, the obtained solution is placed in a sterile vial, freeze-dried in a freeze dryer, and sealed. That is, the yellow levosimendan freeze-dried powder preparation of the present invention is obtained.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com